Clinical drug investigation is a crucial phase in the development of pharmaceuticals, encompassing a meticulous process that evaluates the safety, efficacy, and tolerability of new therapeutic agents. This multifaceted undertaking involves rigorous testing through clinical trials, each comprising distinct phases. Phase I primarily focuses on safety, examining the drug's effects on a small group of healthy volunteers. Subsequently, Phase II delves deeper into efficacy, assessing the drug's impact on a larger patient population. Throughout these phases, meticulous data collection and analysis are imperative to draw meaningful conclusions. Regulatory bodies play a pivotal role in overseeing and approving these investigations, ensuring adherence to ethical standards and safeguarding participant well-being. The translational nature of clinical drug investigation bridges the gap between preclinical research and real-world application, fostering advancements in medical science and offering hope for innovative therapeutic solutions. As technologies evolve, the integration of biomarkers and personalized medicine approaches enhances the precision and efficiency of these investigations. Collaboration between pharmaceutical companies, research institutions, and healthcare professionals remains integral to the success of clinical drug investigations, driving progress in the pursuit of safer and more effective treatments for a myriad of health conditions.
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Exploring classical ayurvedic drugs in hypertension
Prashant Bhokardankar, Datta Meghe Ayurved College, India
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : A unique role and and impact of catalytic antibodies (abzymes) in clinical practice: A novel strategy for predicting and preventing relapse in chronic autoimmune conditions
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promise of nanotechnology in personalized & precision medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promising future of the unique translational tool to manage beta-cell population renewal and regeneration to secure the post-diabetic period
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Easily injectable, organic solvent free self assembled hydrogel platform for endoscope mediated gastrointestinal polypectomy
Hitasha Vithalani , IIT Gandhinagar, India